| Keywords: |
cancer chemotherapy; cancer survival; survival analysis; leukemia; neutropenia; fluorouracil; cancer risk; drug efficacy; drug safety; risk benefit analysis; antineoplastic agents; cancer adjuvant therapy; chemotherapy, adjuvant; methotrexate; antineoplastic agent; metastasis; breast cancer; mucosa inflammation; nausea; vomiting; editorial; cyclophosphamide; breast neoplasms; cancer research; drug research; epirubicin; high risk population; neoplasms, second primary; alopecia; drug induced disease; myelodysplasia; humans; human; female
|
